An observational study in Primary Immunodeficiency, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 3 sites in 3 countries. Open to participants aged 1 Day to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID) — 11 open to participants now, 11 under way, none of them phase 3. Primary Immunodeficiency Diseases · National Institute of Allergy and Infectious Diseases (NIAID).
Among the 16 studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2019, is one of 11 observational ones, and was the 13th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →11 of the 16 studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 4 countries. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 2–120 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–75 · Men only
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–75 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 1 days–90 yrs · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 1 days–100 yrs · Healthy volunteers
By country, each count listing its studies:
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 1 Day to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 4 1
First in 1995; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 137 across 77 observational studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 8 across the 5 interventional studies, 1,190 across the 11 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.
Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.
2 of the studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04864886National Institute of Allergy and Infectious Diseases (NIAID)Metabolic Profiling of Immune Responses in Immune-mediated Diseases | 2027-06-30 |
| NCT05189925National Institute of Allergy and Infectious Diseases (NIAID)NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD) | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Primary Immunodeficiency Diseases by National Institute of Allergy and Infectious Diseases (NIAID), from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background:
The immune system helps the body fight infections. Primary immunodeficiency disorders (PIDs) are diseases that make it easier for people to get sick. Many PIDs are inherited. This means parents can pass them on to their children. Knowing what causes a person s PID is important to decide what treatment to give them.
Objective:
To test samples from people with a PID or people related to someone with a PID to find out what causes PIDs.
Eligibility:
People ages 99 or younger who have a PID or have a relative with a PID
Design:
Participants will be screened with a medical history over the phone. They may need to give permission for researchers talk to their doctors about their health. Their relatives may be contacted to see if they want to join the study.
Participants will give samples. These could be:
Blood: Participants blood will be taken from a vein in an arm, or with a prick on the finger or heel for children.
Saliva, urine, or stool: Participants will provide each sample in a special cup.
Nose or cheek swab: Participants will rub the skin inside their nose or cheek using a cotton swab.
Cord blood: If participants have a baby during the study, blood will be collected from the baby s umbilical cord after it is born.
Samples from medical procedures: If, during the study, the participants have a medical procedure that collects samples, the samples may be used for the study.
Study Design:
This is a prospective sample collection protocol to receive send-in biological samples. Participants will not be seen at the NIH for study visits. Under this protocol, genetic and molecular tests will be performed on samples to improve understanding of PIDs. Findings relevant to participants health and medical care will be returned to them and their referring healthcare providers.
Primary Objective:
To achieve genetic and immunologic characterization of known or suspected disorders of the immune system.
Primary Endpoints:
This is a sample collection protocol to receive send-in samples (blood, tissue, and other bodily fluids) from patients with known or suspected primary immunodeficiency disorder (PID) and their relatives. Under this protocol, genetic and molecular tests will be performed on samples to improve understanding of PIDs and immune system abnormalities. Findings relevant to participants health and medical care will be returned to them and their referring healthcare providers.
Patients with Primary Immune Deficiency or Dysregulatory Disorder and their biological relatives will be referred by healthcare providers worldwide.@@@@@@
Participants enrolled onto this protocol must meet all of the following criteria:
Meets 1 of the following criteria:
EXCLUSION CRITERIA:
Individuals meeting any of the following criteria will be excluded from study participation:
INCLUSION/EXCLUSION OF SPECIAL POPULATIONS:
Children: Children are eligible to participate in this study because PIDs may present in early childhood and results of some research tests may inform participants future medical care. Additionally, the study poses no more than minimal risk.
Pregnant women and neonates: Pregnant women can participate in this study. Research testing on samples from pregnant women may help us learn about changes in the immune systems of immunodeficient patients during pregnancy, which is important knowledge that could not be obtained from nonpregnant individuals. Research testing of pregnant women with known or suspected PIDs could provide insight into the fetus s health risks, which may help guide clinical management during and after pregnancy. We may request cord blood samples at delivery to process right away or freeze. Cord blood is a unique source of stromal cells that may be characterized or modified for research purposes. Additionally, this study poses no more than minimal risk, including to participants who are pregnant and their fetuses. Similarly, neonates (including nonviable neonates or those of uncertain viability) may be enrolled in this study as it does not involve more than minimal risk and blood volumes will be limited based on the clinical status of each participant. Each individual providing consent will be fully informed regarding the reasonably foreseeable impact of the research on the neonate, and individuals engaged in the research will have no part in determining the viability of a neonate. Further, neonates of uncertain viability are eligible because all the following criteria are met:
Nonviable neonates are also eligible because all the following criteria are met:
Decisionally impaired adults: Adults who are unable to consent are excluded from study participation. Enrolled participants who temporarily lose the ability to consent during study participation may continue in the study in accordance with NIH Human Research Protections Program (HRPP) Policy 403 Research with Subjects Lacking Capacity to Consent; the study poses no more than minimal risk and may hold a prospect of direct benefit as results of some research tests may inform participants future medical care. However, enrolled participants who permanently lose the ability to consent during study participation will be withdrawn.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological relative (mother, father, siblings, children, grandparents, aunts, uncles, or first cousins) of patient, with no clinical evidence of having a PID.
Patients with PID, which may be defined by laboratory and/or clinical findings on 2 or more occasions that are consistent with a defect in innate or adaptive immunity.
Identification of patients with abnormalities of the immune system that may be enrolled in other NIH protocols
Identification of patients with abnormalities of the immune system that may be enrolled in other NIH protocols. To achieve genetic and immunologic characterization of known or suspected disorders of the immune system.
Time frame: Duration of participant enrollment
Identification of genetic variants that are associated with PID.
To achieve genetic and immunologic characterization of known or suspected disorders of the immune system.
Time frame: Duration of participant enrollment
Identification of molecular and functional abnormalities associated with known or novel forms of PID (repository study).
Identification of molecular and functional abnormalities associated with known or novel forms of PID (repository study).
Time frame: Duration of participant enrollment
Plan to share: No — The primary focus of this study is to identify genetic variants associated with PID to achieve genetic and immunologic characterization of known or suspected disorders of the immune system
Started Jul 2019 (actual). Primary completion is estimated for Mar 2038, 224 months after the start.
Of 50 observational studies under Primary Immunodeficiency Diseases, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 30. This study's planned 224 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Primary Immunodeficiency Diseases →
National Institute of Allergy and Infectious Diseases (NIAID) →